EU MDR vs FDA: why your device classification doesn't simply translate

Teams targeting both the EU and US markets often assume a single regulatory assessment can be “translated” between jurisdictions.

This paper explains why EU MDR and FDA classification use fundamentally different logic, where that divergence typically shows up for medical device software, and why running both assessments in parallel — rather than sequentially — is what actually protects a dual-market development plan.